U.S. Clean Tech Industry At A Crossroads

U.S. Clean Tech Industry At A Crossroads

April 20, 2011

Click on the logo to the right to read a guest blog by Jim Matheson on the New England Clean Energy Council website.

 

Joule Unlimited, Inc.

Joule Secures First of Multiple Sites to Host Solar Fuel Production

Joule Secures First of Multiple Sites to Host Solar Fuel Production

May 5, 2011

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Marking another milestone in its advance towards commercialization, Joule Unlimited, Inc. today announced the signing of a lease agreement providing access to 1,200 acres in Lea County, New Mexico, with the potential to scale the project up to 5,000 acres for production of renewable diesel and ethanol directly from sunlight and waste CO2. The agreement with Lea County is the first to be completed as part of Joule’s production facility siting program.

Concert Pharmaceuticals, Inc.

Concert Pharmaceuticals Presents Preclinical Data on Novel Deuterium-Containing Drug Compound at Antiepileptic Drug Trials XI Conference

Concert Pharmaceuticals Presents Preclinical Data on Novel Deuterium-Containing Drug Compound at Antiepileptic Drug Trials XI Conference

May 2, 2011

LEXINGTON, Mass.--(BUSINESS WIRE)--Concert Pharmaceuticals, Inc. today announced that C-10068, a novel deuterium-containing sigma-1 agonist, was found to have activity in preclinical models of epilepsy, neuroprotection and neuropathic pain. C-10068 is based on a molecule that was reported to have preclinical anti-convulsant efficacy, but was limited by poor metabolic stability resulting in low oral bioavailability. Applying its DCE Platform™ (deuterated chemical entity platform), Concert improved the compound’s metabolic stability by selective incorporation of deuterium.

Brain Storm: David Berry Profile in Boston Magazine

Brain Storm: David Berry Profile in Boston Magazine

April 20, 2011

"David Berry is one of the most brilliant thinkers you’ve never heard of. Starting in 2012 he’s going to eliminate our dependence on fossil fuels using little more than algae. (Okay, it’s technically cyanobacteria, but you know what we mean.) He might have done it sooner, but he’s also working on curing cancer and eradicating global hunger."

Excerpts from Boston Magazine story. 

Click Boston Magazine logo to view full story.

Joule Unlimited, Inc.

On the hunt for green-tech game changers

On the hunt for green-tech game changers

April 22, 2011

In a CNET NEWS story, Flagship's Noubar Afeyan was quoted discussing Joule Unlimited and the pace and scale of green technology innovation at the Yale Climate and Energy Institute's annual conference.

Click here to view the full story on cnet.

TARIS Biomedical, Inc.

TARIS CLOSES $18.3 MILLION SERIES B FINANCING

TARIS CLOSES $18.3 MILLION SERIES B FINANCING

April 13, 2011

Lexington, MA – TARIS Biomedical®, a specialty pharmaceutical company pioneering the development of innovative, targeted therapies using drug delivery to treat bladder diseases, announced today that it has raised $18.3 million of new capital in connection with its Series B equity financing. Third Rock Ventures, a new investor, led the round and all existing TARIS investors, Flagship Ventures, Flybridge Capital Partners and Polaris Venture Partners, participated. The company’s prior bridge financing was also converted into equity in connection with the round.

AVEO Pharmaceuticals, Inc.

AVEO Pharmaceuticals Appoints Henri A. Termeer to its Board of Directors

AVEO Pharmaceuticals Appoints Henri A. Termeer to its Board of Directors

April 12, 2011

CAMBRIDGE, Mass.--(BUSINESS WIRE)--AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) today announced the appointment of industry veteran Henri A. Termeer, outgoing chairman, president and chief executive officer of Genzyme Corporation, to its Board of Directors.

Ensemble Therapeutics Corporation

Ensemble Therapeutics Achieves Milestone in Bristol-Myers Squibb Collaboration

Ensemble Therapeutics Achieves Milestone in Bristol-Myers Squibb Collaboration

April 12, 2011

Major Progress Developing Ensemblins Against Challenging Drug Targets Yields Payment to Ensemble and Transfer of Successful Program to BMS

Macrocycle Platform Reaches New Levels of Productivity against Challenging Drug Targets

Seventh Sense Biosystems, Inc.

Seventh Sense Biosystems Receives Gold Medal Edison Award

Seventh Sense Biosystems Receives Gold Medal Edison Award

April 8, 2011

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seventh Sense Biosystems, Inc., an early stage, venture-backed company developing a new generation of health diagnostics products, announced today that its Touch Activated Phlebotomy™ (TAP) technology has received the Gold Medal Award from The Edison Awards™ in the Science and Medicine – Diagnostic Aids Segment. These annual awards recognize innovation, creativity and ingenuity. 

Mascoma Corporation

Ethanol Industry Hoping for Surge

Ethanol Industry Hoping for Surge

March 31, 2011

 

Flagship portfolio company, Mascoma, featured in The New York Times:

"Another biofuels company, Mascoma, plans a $350 million, 40 million-gallon-a-year cellulosic plant in Michigan, and construction is expected to start this year, according to its chief executive, Bill Brady. Mascoma already operates a smaller demonstration plant in Rome, N.Y."

To view full article click on below: